May 18, 2022
On Wednesday, 11 May, thought leaders from across psychedelic healthcare converged at the National Gallery for the inaugural, and sold
May 10, 2022
The following article was originally published by Psychedelic Alpha. As the psychedelic sector continues to mature, stakeholders from an ever-growing
May 10, 2022
Biomind Labs At PSYCH Symposium Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s
May 4, 2022
Negev Capital With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments
April 27, 2022
At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for
April 19, 2022
On 19 April 1943, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the psychedelic medicine. When Hofmann
April 13, 2022
More than 280 million people suffer from depression worldwide, with many not responding to conventional treatments, and over 5,000 lives
April 6, 2022
Psilocybin was first isolated in 1958 by Albert Hofmann and is one of the most researched psychedelic medicines, with over
March 30, 2022
At the end of 2021, UK-based COMPASS Pathways shared positive results from its Phase IIb clinical trial of COMP360 psilocybin
March 23, 2022
Acceleration the adoption and accessibility of psychedelic healthcare is crucial to drive innovation in mental health care and improved patient
March 16, 2022
At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across
March 9, 2022
Novamind today announced it has been contracted by the Usona Institute to provide a research site for its Phase II
